Epithelioid sarcoma
MONDO:0017387An aggressive malignant neoplasm of uncertain differentiation, characterized by the presence of epithelioid cells forming nodular patterns. The nodules often undergo central necrosis, resulting in a pseudogranulomatous growth pattern. It usually occurs in young adults. The most common sites of involvement are the extremities (distal-type epithelioid sarcoma), and less frequently the pelvis, perineum, and genital organs (proximal-type epithelioid sarcoma).
Also known as: ES, epithelioid cell sarcoma, epithelioid sarcoma
2827 clinical trials for this condition and its sub-types, 20 tagged with Epithelioid sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Epithelioid sarcoma
-
Adult epithelioid sarcoma 0 trials
-
Childhood epithelioid sarcoma 0 trials
-
Peripheral epithelioid sarcoma 0 trials
-
Proximal-type epithelioid sarcoma 0 trials
1 sub-type
-
Can a new drug shrink Hard-to-Treat childhood cancers?
Disease control Recruiting nowThis trial is testing an experimental drug called ONO-4538HSC (nivolumab) in children with advanced solid tumors that have not responded to standard treatments, and in patients with epithelioid sarcoma. The goal is to see if the drug is safe, tolerable, and effective at shrinking…
Phase 1/2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Immune booster drug tested on rare cancers
Disease control Recruiting nowThis study is testing a drug called pembrolizumab in people with ultra-rare sarcomas, a group of very uncommon cancers. The drug works by releasing the immune system's brakes so it can attack cancer cells. Researchers want to see if it can shrink tumors or stop them from growing,…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New stem cell approach aims to fight tough childhood cancers
Disease control Recruiting nowThis study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…
Phase 1/2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Last-Resort drug opens for rare cancer patients
Disease control Expanded accessThis program provides early access to ubamatamab for people with two rare and aggressive cancers: renal medullary carcinoma and epithelioid sarcoma. The drug is given on a case-by-case basis to those who have no other treatment options. The goal is to offer a potential treatment …
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New experimental pill takes on tough cancers
Disease control Recruiting nowThis study tests an experimental drug called HH2853 in people with certain types of blood cancer (non-Hodgkin lymphoma) or advanced solid tumors that have come back or stopped responding to treatment. The drug is taken as a tablet twice a day. The main goals are to find the safes…
Phase 1/2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Scientists launch deep dive into rare sarcomas to unlock immune secrets
Knowledge-focused Recruiting nowThis study is collecting tumor and blood samples from 400 people with rare soft tissue sarcomas to learn how their immune system reacts to the cancer. Researchers will also track patients' health over time to see how the disease progresses. The goal is to find clues that could le…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Researchers watch and learn: no new treatment for rare sarcoma
Knowledge-focused Recruiting nowThis study is observing 100 people with epithelioid sarcoma, a rare cancer. Researchers will track what treatments patients receive and how they respond. The goal is to better understand the disease and current care, not to test a new drug.
Sponsor: Italian Sarcoma Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC